Researchers conducted a study that investigated the risk for cardiovascular and bleeding events according to groups of antithrombotic medications and subtypes of NSAIDs. The first diagnosed MI in the nationwide cohort study was retrieved from 108,232 patients that they have accessed the Health Insurance Review and Assessment Service database between 2009 and 2013.
Based on their prescribed antithrombotic medications, the patients were divided into groups with the thromboembolic cardiovascular and clinically relevant bleeding events as the study outcomes.
Concomitant NSAID treatment significantly elevated the risk for cardiovascular events and bleeding events compared with no NSAID treatment over a mean follow-up of 2.3 years. Celecoxib and meloxicam showed the lowest risk of cardiovascular and bleeding events among NSAID subtypes.
The authors stated in their research that although NSAID treatment should be avoided after MI, celecoxib and meloxicam could be considered as alternative options in cases in which NSAID use is unavoidable.
Share the post!